Company intelligence / Profile preview

Milligen

Labège, Occitanie, France

Ownership: Private
Development stage: Other

Overview

MilliGen was a French biotechnology company specializing in the development and production of custom monoclonal antibodies and diagnostic tools. Founded as a spin-off from the French National Centre for Scientific Research (CNRS), the company focused on proteomics and the identification of novel biomarkers for clinical diagnostics. MilliGen provided specialized services in antibody engineering and the development of immunoassays for the pharmaceutical and research sectors. The company was eventually acquired by the Belgian diagnostics firm Innogenetics in 2003 to strengthen its protein expression and antibody capabilities.

Modalities: Monoclonal antibodyProtein
Industry: Protein Biomarker Diagnostics

Partnerships

CNRSInnogenetics

Beyond the preview

Go deeper on Milligen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Milligen.

Explore the full profile